last posts

QSYMIA (Phentermine-Topiramate) Drug Overview and Market Forecast to 2032

techsm5

DUBLIN, January 3, 2023 /PRNewswire/ — The report “QSYMIA (Phentermine-Topiramate), Drug Insight and Market Forecast – 2032” has been added to from ResearchAndMarkets.com offer.

Research and Markets Logo

Research and Markets Logo

The report provides information on the mechanism of action, dosage, and administration, as well as research and development activities, including regulatory milestones, as well as other development activities.

Additionally, it also includes future market assessments including QSYMIA (Phentermine-topiramate) market forecast, 7MM obesity analysis, descriptive analysis such as SWOT, analyst opinions, a comprehensive overview of market competitors and a brief on other emerging therapies in Obesity.

Medication Summary

QSYMIA, formerly known as Qnexa, is a combination of phentermine, a sympathomimetic amine appetite suppressant, and time-release topiramate, an antiepileptic drug.

It is indicated as an adjunct to a calorie restricted diet and increased physical activity for chronic weight management in adults with a baseline body mass index (BMI) of 30 kg/m2 or more (obese) or 27 kg /m2 or more (overweight). ) in the presence of at least one weight-related comorbidity such as hypertension, type 2 diabetes or dyslipidemia.

The recommended dosage regimen of QSYMIA is 3.75 mg/23 mg (phentermine 3.75 mg/topiramate 23 mg extended release) daily for 14 days; then increase to 7.5 mg/46 mg daily. Interrupt or increase dosage if 3% weight loss is not achieved after 12 weeks with 7.5 mg/46 mg or if 5% weight loss is not achieved after 12 weeks with a maximum daily dose of 15 mg/92 mg.

Phentermine is a sympathomimetic amine with similar pharmacological activity to amphetamine (d- and d/l-amphetamine), the prototype drug of this class used in obesity. Drugs of this class used in obesity are commonly referred to as ‘anorectics’ or ‘anorectics’.

The effect of phentermine on chronic weight management is likely mediated by the release of catecholamines in the hypothalamus, resulting in reduced appetite and decreased food intake, but other metabolic effects may also be involved. . The exact mechanism of action is not known.

The precise mechanism of action of topiramate on chronic weight management is not known. The effect of topiramate on chronic weight management may be due to its appetite suppressing and satiety enhancing effects mediated by a combination of pharmacological effects, including increased activity of gamma-aminobutyrate neurotransmitter, modulation of voltage-gated ion channels, inhibition of AMPA/kainite excitatory glutamate receptors, or inhibition of carbonic anhydrase.

The precise mechanism of action of topiramate on chronic weight management is not known. The effect of topiramate on chronic weight management may be due to its appetite suppressing and satiety enhancing effects mediated by a combination of pharmacological effects, including increased activity of gamma-aminobutyrate neurotransmitter, modulation of voltage-gated ion channels, inhibition of AMPA/kainite excitatory glutamate receptors, or inhibition of carbonic anhydrase.

Report scope

The report provides information on:

  • A comprehensive product overview including description of QSYMIA (Phentermine-topiramate), mechanism of action, dosage and administration, research and development activities in obesity.

  • Elaborate details of QSYMIA (Phentermine-topiramate) regulatory milestones and other development activities have been provided in this report.

  • The report also highlights QSYMIA (Phentermine-topiramate) research and development activity in obesity in detail across United States, Europe and Japan.

  • The report also covers patent information with expiration time around QSYMIA (Phentermine-topiramate).

  • The report contains predicted sales of QSYMIA (Phentermine-topiramate) for obesity through 2032.

  • Comprehensive coverage of emerging late-stage therapies for obesity.

  • The report also presents the SWOT analysis with analyst views for QSYMIA (Phentermine-topiramate) in Obesity.

Report Highlights

  • In the coming years, the market scenario for obesity is bound to change due to extensive research and additional healthcare expenditures across the world; which would expand the size of the market to enable drug manufacturers to further penetrate the market.

  • The companies are developing therapies that focus on new approaches to treat/improve disease state, assess challenges and seek opportunities that may influence QSYMIA (Phentermine-topiramate) dominance.

  • Other emerging obesity products are expected to give QSYMIA (Phentermine-topiramate) fierce competition and the launch of emerging late-stage therapies in the near future will have a significant impact on the market.

  • A detailed description of regulatory milestones and development activities provides the current development scenario of QSYMIA (Phentermine-topiramate) in obesity.

  • In-depth analysis of QSYMIA (Phentermine-topiramate) forecast sales data from 2022 to 2032 will support customers in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of QSYMIA (Phentermine-topiramate) in Obesity .

Answers to key questions

  • What is the product type, route of administration and mechanism of action of QSYMIA (Phentermine-topiramate)?

  • What is the clinical trial status of the study related to QSYMIA (Phentermine-topiramate) in obesity and the date of study completion?

  • What are the major collaborations, mergers and acquisitions, licensing and other activities related to the development of QSYMIA (Phentermine-topiramate)?

  • What are the key designations that have been granted to QSYMIA (Phentermine-topiramate) for obesity?

  • What is the predicted market scenario of QSYMIA (Phentermine-topiramate) for Obesity?

  • What are the expected sales of QSYMIA (Phentermine-topiramate) in the top seven countries including United States, Europe (Germany, France, Italy, Spainand the UK), and Japan?

  • What other emerging products are available in obesity and how do they compete with QSYMIA (Phentermine-topiramate) for obesity?

  • What are the late-stage emerging therapies being developed for the treatment of obesity?

Main topics covered:

1. Presentation of the report

2. Presentation of QSYMIA (Phentermine – topiramate)
2.1. Product details
2.2. Clinical development
2.2.1. Clinical studies
2.2.2. Information on clinical trials
2.2.3. Safety and efficiency
2.3. Regulatory milestones
2.4. Other development activities
2.5. Product Profile

3. Competitive landscape (marketed therapies)

4. Competitive Landscape (Emerging Therapies)*

5. Market assessment of QSYMIA (Phentermine – topiramate)
5.1. Market Prospects of QSYMIA (Phentermine – topiramate) in Obesity
5.2. 7MM market analysis
5.2.1. Market size of QSYMIA (Phentermine – topiramate) in 7MM for obesity
5.3. Market analysis by country
5.3.1. QSYMIA (Phentermine – Topiramate) Market Size United States for obesity
5.3.2. QSYMIA (Phentermine – Topiramate) Market Size Germany for obesity
5.3.3. QSYMIA (Phentermine – Topiramate) Market Size France for obesity
5.3.4. QSYMIA (Phentermine – Topiramate) Market Size Italy for obesity
5.3.5. QSYMIA (Phentermine – Topiramate) Market Size Spain for obesity
5.3.6. QSYMIA (Phentermine – Topiramate) Market Size in Global UK for obesity
5.3.7. QSYMIA (Phentermine – Topiramate) Market Size Japan for obesity

6. SWOT Analysis

7. Analyst Views

8. Appendix

9. Editor Capabilities

10. Disclaimer

11. About the editor

12. Report purchase options

For more information about this report visit https://www.researchandmarkets.com/r/wxh1kw

Media Contact:

Research and Markets
Laura Woodsenior
press@researchandmarkets.com

For EST office hours, call +1-917-300-0470
For USA/CAN call toll free +1-800-526-8630
For GMT office hours call +353-1-416-8900

US Fax: 646-607-1907
Fax (outside the US): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

Quote

Quote

View original content: https://www.prnewswire.com/news-releases/qsymia-phentermine-topiramate-drug-insights-and-market-forecasts-to-2032-301712347.html

SOURCE Research and Markets

techsm5

Comments



Font Size
+
16
-
lines height
+
2
-